IP Verse

Antibodies With Modified Affinity To Fcrn That Promote Antigen Clearance - EP2552955

The patent EP2552955 was granted to Chugai Seiyaku Kabushiki Kaisha on May 3, 2017. The application was originally filed on Mar 30, 2011 under application number EP11714860A. The patent is currently recorded with a legal status of "Revoked".

EP2552955

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP11714860A
Filing Date
Mar 30, 2011
Status
Revoked
Sep 23, 2022
Grant Date
May 3, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

SHIRE HUMAN GENETIC THERAPIESFeb 5, 2018HOFFMANN EITLEADMISSIBLE
TILLOTTS PHARMAFeb 5, 2018LEDERER & KELLERADMISSIBLE
TILLOTTS PHARMAFeb 5, 2018LEDERER & KELLER PATENTANWALTE PARTNERSCHAFT MBBADMISSIBLE
ABLYNXFeb 2, 2018HOFFMANN EITLEADMISSIBLE
GLAXO GROUPFeb 2, 2018DRURYADMISSIBLE
MURPHYFeb 2, 2018COOLEY UKADMISSIBLE
ALEXION PHARMACEUTICALSFeb 2, 2018J A KEMPWITHDRAWN

Patent Citations (65) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0125023
DESCRIPTIONEP0239400
DESCRIPTIONEP2154157
DESCRIPTIONJP2008504970
DESCRIPTIONJP2010079667
DESCRIPTIONJP2010250830
DESCRIPTIONJPH059878B
DESCRIPTIONUS2007141052
DESCRIPTIONWO0042072
DESCRIPTIONWO0061739
DESCRIPTIONWO02060919
DESCRIPTIONWO02079255
DESCRIPTIONWO0220565
DESCRIPTIONWO0231140
DESCRIPTIONWO0232925
DESCRIPTIONWO03002609
DESCRIPTIONWO2004044011
DESCRIPTIONWO2004058821
DESCRIPTIONWO2004106377
DESCRIPTIONWO2005037989
DESCRIPTIONWO2005040229
DESCRIPTIONWO2006020114
DESCRIPTIONWO2006031370
DESCRIPTIONWO2006053301
DESCRIPTIONWO2006067847
DESCRIPTIONWO2006067913
DESCRIPTIONWO2006073941
DESCRIPTIONWO2006105338
DESCRIPTIONWO2007041635
DESCRIPTIONWO2008045140
DESCRIPTIONWO2008092117
DESCRIPTIONWO2009086320
DESCRIPTIONWO2009113742
DESCRIPTIONWO2009125825
DESCRIPTIONWO2010033279
DESCRIPTIONWO9201047
DESCRIPTIONWO9203918
DESCRIPTIONWO9220791
DESCRIPTIONWO9306213
DESCRIPTIONWO9311236
DESCRIPTIONWO9312227
DESCRIPTIONWO9319172
DESCRIPTIONWO9402602
DESCRIPTIONWO9501438
DESCRIPTIONWO9501937
DESCRIPTIONWO9515388
DESCRIPTIONWO9515393
DESCRIPTIONWO9602576
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9813388
DESCRIPTIONWO9846777
DESCRIPTIONWO9954342
EXAMINATIONWO2009086320
EXAMINATIONWO2009125825
INTERNATIONAL-SEARCH-REPORTUS2007148164
INTERNATIONAL-SEARCH-REPORTWO0042072
OPPOSITIONEP2275443
OPPOSITIONJP2010079667
OPPOSITIONJP2010250830
OPPOSITIONWO03105757
OPPOSITIONWO2009086320
OPPOSITIONWO2009125825
OPPOSITIONWO2011111007
OPPOSITIONWO2016000813

Non-Patent Literature (NPL) Citations (55) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- Alignment of constant amino acid sequences from D1-
OPPOSITION- Alignment of the amino acid sequences of the Fc regions of the antibodies exemplified in D7 N/A-
OPPOSITION- Alignment of variable heavy and light chain amino acid sequences from D1-
OPPOSITION- "Antibody Engineering: design for specific applications", David J. King, Applications And Engineering Of Monoclonal Antibodies, (19980000), pages 68 - 71, ISBN 0748404228, XP055461062-
OPPOSITION- DAVYDOV, "Omalizumab (Xolair) for Treatment of Asthma", Am Fam Physician, (20050000), vol. 71, pages 341 - 342, XP055461500-
OPPOSITION- Experimental data characterizing the binding of rituximab to its antigen CD 20 and to human FcRn-
OPPOSITION- Ito, "The His-probe method: Effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS Letters, (19920000), vol. 309, no. 1, pages 85 - 88, XP008123385-
OPPOSITION- Molina et al, "Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells.", CANCER RESEARCH, (20010600), vol. 61, no. 12, pages 4744 - 4749, XP002408598-
OPPOSITION- O'DONOVAN et al., "EGFR and HER-2 Antagonists in Breast Cancer", Anticancer Research, (20070000), vol. 27, pages 1285 - 1294, XP055463009-
OPPOSITION- PRESTA et al., "Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumours and other disorders", Cancer Res., (19971015), vol. 57, no. 20, pages 4593 - 4599, XP055461641-
OPPOSITION- "Rituxan TM (Rituximab) Description", IDEC Pharmaceuticals Corp., (19971100), pages 1 - 2, XP055461625-
OPPOSITION- Soudabeh et al, "In silico design, construction and cloning of Trastuzumab humanized monoclonal antibody: A possible biosimilar for Herceptin", Advanced Biomedical Research, (20120000), vol. 1, no. 1, pages 1 - 6, XP055461164-
OPPOSITION- WAELBROECK, "The pH dependence of insulin binding. A quantitative study.", The Journal of Biological Chemistry, (19820000), vol. 257, no. 14, pages 8284 - 8291, XP055461615-
OPPOSITION- WARD et al., "Evidence to support the cellular mechanism involved in serum IgG homeostasis in humans", Int Immunol., (20030200), vol. 15, no. 2, pages 187 - 95, XP055461636-
OPPOSITION- WELCH, "Adalimumab (Humira) for the Treatment of Rheumatoid Arthritis", Am Fam Physician, (20080000), vol. 78, pages 1406 - 1408, XP055461499-
OPPOSITION- YANG et al., "Dataset of the binding kinetic rate constants of anti-PCSK9 antibodies obtained using the Biacore T100, ProteOn XPR36, Octet RED384, and IBIS MX96 biosensor platforms", Data in Brief, (20160000), vol. 8, pages 1173 - 1183, XP055461620-
OPPOSITION- PRESTA LG, "Molecular engineering and design of therapeutic antibodies", Curr. Op. Immunol., (20080800), vol. 20, pages 460 - 470, XP025771205
OPPOSITION- STROHL, "Optimization of Fc-mediated effector functions of monoclonal antibodies", Current Opinion in Biotechnology, (20091104), vol. 20, pages 685 - 691, XP026778879
OPPOSITION- PATTON et al., "An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen", Journal of Immunological Methods, (20050000), vol. 304, pages 189 - 194, XP002588698
OPPOSITION- G URBAXANI et al., "Analysis of a family of antibodies with different half lives in mice fails to find a correlation between affinity for FcRn and serum half life", Molecular Immunology, (20060000), vol. 43, pages 1462 - 1473, XP005305320
OPPOSITION- Irani, "Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases", MOLECULAR IMMUNOLOGY, (20150000), vol. 67, no. 2, pages 171 - 182, XP029246901
OPPOSITION- ATHERTON, "Acid-base balance: maintenance of plasma pH", Anaesthesia & Intensive Care Medicine, (20090000), vol. 10, no. 11, pages 557 - 561, XP026709829
OPPOSITION- RAGHAVAN et al., "Analysis of the pH Dependence of the Neonatal Fc Receptor/lmmunoglobulin G Interaction Using Antibody and Receptor Variants", Biochemistry, (19950000), vol. 34, doi:10.1021/bi00045a005, pages 14649 - 14657, XP009044243
OPPOSITION- BURMEISTER et al., "Crystal structure of the complex of rat neonatal Fc receptor with FC", Nature, (19941124), vol. 372, doi:10.1038/372379a0, pages 379 - 383, XP000876647
OPPOSITION- VACCARO et al., "Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels", Nature Biotechnology, (20050000), vol. 23, no. 10, pages 1283 - 1288, XP055049342
OPPOSITION- ZALEVSKY et al., "Enhanced antibody half-life improves in vivo activity", Nat. Biotechnol., (20100117), vol. 28, no. 2, pages 157 - 9, XP055395562
OPPOSITION- ZALEVSKY et al., "Enhanced antibody half-life improves in vivo activity", Nature Biotechnology, (20100000), vol. 28, no. 2, pages 157 - 159, XP055395562
OPPOSITION- ZALEVSKY et al., "Enhanced antibody half-life improves in vivo activity", Nature Biotechnology, (20100200), vol. 28, pages 157 - 159, XP055395562
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nat. Biotechnol., (20101017), vol. 28, no. 11, pages 1203 - 1208, XP055306183
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nature Biotechnology, (20100000), vol. 28, no. 11, pages 1203 - 1208, XP055306183
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nature Biotechnology, (20101017), vol. 28, no. 11, pages 1203 - 1207, XP055306183
OPPOSITION- IGAWA et al., Nature Biotechnology, (20101017), vol. 28, pages 1203 - 1208, XP055306183
OPPOSITION- ROOPENIAN et al., "FcRn: the neonatal Fc receptor comes of age", Nature Reviews Immunology, (20070000), vol. 7, pages 715 - 725, XP002753502
OPPOSITION- Vaccaro et al, "Divergent activities of an engineered antibody in murine and human systems have implications for therapeutic antibodies", PNAS, (20060000), vol. 103, no. 49, XP002518923
OPPOSITION- SHIELDS et al., "High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcyR", J. Biol. Chemistry, (20010302), vol. 276, no. 9, pages 6591 - 6604, XP002971008
OPPOSITION- SHIELDS et al., "High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR", The Journal of Biological Chemistry, (20010000), vol. 276, no. 9, pages 6591 - 6604, XP002971008
OPPOSITION- Shields Robert L. et al, "High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR", Journal of Biological Chemistry, (20010000), vol. 276, no. 9, pages 6591 - 6604, XP002971008
OPPOSITION- DALL'ACQUA et al., "Properties of Human IgG1s Engineered for Enhance Binding to the Neonatal Fc Receptor", The Journal of Biological Chemistry, vol. 281, no. 33, doi:10.1074/jbc.M604292200, pages 23514 - 23524, XP002404904
OPPOSITION- Dall'Acqua et al, "Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn).", Journal of Biological Chemistry, (20060000), vol. 281, no. 33, pages 23514 - 23524, XP002404904
OPPOSITION- Datta Mannan et al, "Monoclonal antibody clearance. Impact of modulating the interaction of IgG with the neonatal Fc receptor.", Journal of Biological Chemistry, (20070000), vol. 282, no. 3, pages 1709 - 1717, XP055043665
OPPOSITION- Yang, "Maximizing in vivo target clearance by design of pH-dependent target binding antibodies with altered affinity to FcRn.", mAbs, (20170000), vol. 9, no. 7, pages 1105 - 1117, XP055461166
OPPOSITION- GOEBL et al., "Neonatal Fc receptor mediates internalisation of Fc in transfected human endothelial cells", Molecular Biology of the cell, (20080000), vol. 19, doi:10.1091/mbc.E07-02-0101, pages 5490 - 5505, XP055539484
OPPOSITION- PETKOVA et al., "Enhanced half life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease", International Immunology, (20060000), vol. 18, no. 12, doi:10.1093/intimm/dxl110, pages 1759 - 1769, XP002539987
OPPOSITION- DATTA-MANNAN et al., "Humanised IgG1 Variants with Differential Binding Properties to the Neonatal Fc Receptor: Relationship to Pharmacokinetics in Mice and Primates", Drug Metabolism and Disposition, (20070000), vol. 35, doi:10.1124/dmd.106.011734, pages 86 - 94, XP009077715
OPPOSITION- DENG et al., "Pharmacokinetics of Humanized Monoclonal Anti-Tumour Necrosis Factor-a Antibody and Its Neonatal Fc Receptor Variants in Mice and Cynomolgus Monkeys", Drug Metab Dispos, vol. 38, no. 4, pages 600 - 605 13 January 2010, XP055019071
OPPOSITION- YEUNG et al., "A Therapeutic Anti-VEGF Antibody with Increased Potency Independent of Pharmacokinetic Half-life", Cancer, (20100330), vol. 70, pages 3269 - 3277, XP002738426
OPPOSITION- Reverberi and Reverberi, "Factors affecting the antigen-antibody reaction", Blood Transfusion, (20070000), vol. 5, pages 227 - 240, XP055069254
OPPOSITION- YEUNG et al., "Engineering human IGG1 affinity to human neonatal Fc receptor: Impact of affinity improvement on pharmacokinetics in primates", J. Immunol, (20090000), vol. 182, pages 7663 - 7671, XP002566420
OPPOSITION- YEUNG et al., "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", J Immunol., (20090615), vol. 182, pages 7663 - 7671, XP002566420
OPPOSITION- YEUNG et al., "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", Journal of Immunology, (20090000), vol. 182, pages 7663 - 7671, XP002566420
OPPOSITION- Yeung et al, "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", The Journal of Immunology, (20090000), vol. 182, no. 12, pages 7663 - 7671, XP002566420
OPPOSITION- YEUNG et al., "Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates", The Journal of Immunology, (20090000), vol. 182, no. 12, pages 7663 - 7671, XP002566420
OPPOSITION- Dall'Acqua et al, "Increasing the Affinity of a Human IgG1 for the Neonatal Fc Receptor: Biological Consequences", The Journal of Immunology, (20020000), vol. 169, no. 9, pages 5171 - 5180, XP055283699
OPPOSITION- HINTON et al., "An Engineered human IGG1 antibody with longer serum half-life", J. Immunol, (20060000), vol. 176, no. 1, pages 346 - 356, XP002482524
OPPOSITION- HINTON et al., "An Engineered Human IgG1 Antibody with Longer Serum Half-Life", J Immunol., (20060101), vol. 176, pages 346 - 356, XP002484005

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents